- Trials with a EudraCT protocol (78)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
78 result(s) found for: Alkylating Agent.
Displaying page 1 of 4.
EudraCT Number: 2005-005177-29 | Sponsor Protocol Number: EORTC 26052-22053 | Start Date*: 2006-11-10 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma | |||||||||||||
Medical condition: Patients with Glioblastoma Multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007295-14 | Sponsor Protocol Number: 26081-22086 | Start Date*: 2010-11-17 | ||||||||||||||||||||||||||
Sponsor Name:European Organization for Research and Treatment of Cancer (EORTC) | ||||||||||||||||||||||||||||
Full Title: Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma. | ||||||||||||||||||||||||||||
Medical condition: Newly Diagnosed Anaplastic Glioma with Chromosomal co-deletions of 1p and 19q | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000654-23 | Sponsor Protocol Number: EORTC 18032 | Start Date*: 2004-12-09 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group | |||||||||||||
Medical condition: Stage IV Metastatic Melanoma: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001949-26 | Sponsor Protocol Number: 26062-22061 | Start Date*: 2009-05-05 | |||||||||||
Sponsor Name:EORTC European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS | |||||||||||||
Medical condition: Elderly (>65 years of age) patients with newly diagnosed, and histopathologically confirmed, glioblastoma multiforme (GBM, WHO grade IV) , who have had prior surgery/biopsy at diagnosis and who are... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001533-17 | Sponsor Protocol Number: EORTC26053-22054 | Start Date*: 2007-06-25 | |||||||||||
Sponsor Name:EORTC European Organisation for research and treatment of cancer | |||||||||||||
Full Title: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial. | |||||||||||||
Medical condition: anaplastic glioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001088-38 | Sponsor Protocol Number: BAY80-6946/17833 | Start Date*: 2015-12-09 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in p... | |||||||||||||
Medical condition: Patients with relapsed indolent non-Hodgkin's lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Completed) DK (Prematurely Ended) ES (Prematurely Ended) GB (Completed) FR (Ongoing) PL (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) HU (Completed) SK (Ongoing) GR (Restarted) BG (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001787-22 | Sponsor Protocol Number: AC-007-IT | Start Date*: 2012-05-02 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: An open-label, phase II study of Pomalidomide and Dexamethasone (PDex) for previously treated patients with AL amyloidosis | |||||||||||||
Medical condition: Previously treated AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002345-39 | Sponsor Protocol Number: Göteborg University | Start Date*: 2006-02-16 |
Sponsor Name:NOPHO NHL-group | ||
Full Title: B-NHL BFM 04 | ||
Medical condition: B-cell lymphoma or B-ALL in children up to 18 years of age | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002714-11 | Sponsor Protocol Number: EORTC 22033-26033 | Start Date*: 2005-06-06 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study | |||||||||||||
Medical condition: Histologically proven low-grade glioma ♦ Astrocytoma WHO grade II (gemistocytic, fibrillary and protoplasmatic) ♦ Oligoastrocytoma WHO grade II ♦ Oligodendroglioma WHO grade II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Completed) HU (Completed) SE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004081-18 | Sponsor Protocol Number: JCAR017-FOL-001 | Start Date*: 2020-08-04 | |||||||||||||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||||||||||||
Full Title: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (... | |||||||||||||||||||||||
Medical condition: Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Ongoing) AT (Ongoing) ES (Ongoing) DE (Ongoing) FR (Ongoing) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022155-33 | Sponsor Protocol Number: 101-09 | Start Date*: 2011-06-10 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents | |||||||||||||
Medical condition: Indolent B-Cell Non-Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000925-19 | Sponsor Protocol Number: BAY80-6946/17322 | Start Date*: 2015-03-23 |
Sponsor Name:Bayer Healthcare AG | ||
Full Title: A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-2 | ||
Medical condition: Patients with rituximab-refractory indolent non-Hodgkin's lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) IE (Completed) GR (Completed) PL (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2022-001453-23 | Sponsor Protocol Number: G-85974806 | Start Date*: 2023-01-12 |
Sponsor Name:ASATE | ||
Full Title: Pilot safety study of neoadjuvant radiotherapy in patients with glioblastoma. | ||
Medical condition: Glioblastoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011118-47 | Sponsor Protocol Number: L00070IN308B0 | Start Date*: 2009-04-24 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vi... | |||||||||||||
Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) PT (Completed) IT (Completed) ES (Completed) BE (Completed) DE (Completed) AT (Completed) HU (Completed) GB (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004661-15 | Sponsor Protocol Number: CLI-037 | Start Date*: 2005-05-17 |
Sponsor Name:Vion Pharmaceuticals, Inc. | ||
Full Title: A Phase III Randomized Study of CLORETAZINE™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse | ||
Medical condition: Acute Myeloid Leukemia (AML) in First Relapse | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001842-34 | Sponsor Protocol Number: DOXIL-MMY-3001 | Start Date*: 2004-11-29 |
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development | ||
Full Title: A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | ||
Medical condition: Recurred or relapsed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003645-42 | Sponsor Protocol Number: CA209-140 | Start Date*: 2014-02-03 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) Revised protocol 03a, including amendment 04 and 05 | |||||||||||||
Medical condition: Lymphoma. Non-Hodgkin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) ES (Prematurely Ended) IT (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002245-12 | Sponsor Protocol Number: EORTC 18021 | Start Date*: 2005-01-27 | |||||||||||
Sponsor Name:European Organisation for the Research and Treatment of Cancer | |||||||||||||
Full Title: Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group. | |||||||||||||
Medical condition: Uveal melanomas with specific hepatic tropism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004726-91 | Sponsor Protocol Number: 01063 | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:CHRU de Lille | |||||||||||||
Full Title: A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-smal... | |||||||||||||
Medical condition: Unresectable non metastatic stage III non small cell lung carcinoma eligible for concomitant radiochemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003791-37 | Sponsor Protocol Number: KFE2011.06 | Start Date*: 2011-09-30 | |||||||||||
Sponsor Name:Department of Haematology, Aalborg University Hospital | |||||||||||||
Full Title: Pre-Clinical Phase 0 Microdose Study to evaluate the effect of Melphalan, Bortezomib and Dexamethasone on cellular gene-expression. | |||||||||||||
Medical condition: Multiple Myelomatosis (MM). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.